Early Identification and Action in CKD
Completed · Not applicable
Conditions studied: Chronic Kidney Disease, Hypertension
In brief
Chronic kidney disease (CKD) is highly prevalent and associated with significantly increased risk of cardiovascular morbidity and end-stage renal disease. Evidence from randomized clinical trials suggests that treating urinary albumin excretion (UAE), dyslipidemia, and hypertension will reduce these risks. Unfortunately, less than 30% of the CKD population is screened and treated according to recommended guidelines. Using a cluster-randomized, controlled design and clinic-embedded pharmacists, this pilot pragmatic trial will randomize 6 Geisinger primary care clinics (72 patients) to usual care (group 1) or a pharmacist-directed "CKD Action Plan" (group 2). Determining the impact of the CKD Action Plan on screening and treatment guideline adherence is the primary goal of this pilot study.
Key facts
- Study ID
- NCT02208674
- Run by
- Geisinger Clinic
- People needed
- 47
- Starts
- 2014-09-01
- Expected to finish
- 2016-03-01
- Last updated by the study team
- 2016-11-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 18 years of age or older
- eGFRCR value between 45-59 ml/min/1.73m2 in the prior 12 months
- scheduled laboratory appointment for serum creatinine testing within the next 30 days
- average systolic or diastolic blood pressure reading of at least 150 or 85 mm Hg, respectively, during the prior 12 months.
You may not qualify if…
- fewer than 2 blood pressure readings in the prior 12 months,
- pregnancy
- current hospitalization
- life expectancy less than 6 months as determined by the study investigators
Where it is running
- Geisinger Health System — Danville, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.